Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing challenge for patients and ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

“Despite recent advancements with Antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), many patients, including those with HR+ disease, like BriaCell’s first OTS ...

Summary: A new study reveals that immune resilience, a person’s ability to maintain a robust, youthful immune system, plays a critical role in promoting long-term health and extending life. By ...

It's well-known that a person's immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn't appear to hinder the ...

The primary mechanism of action (MOA) of PDL1V is direct cytotoxicity to PD-L1-expressing ... suggesting that targeted delivery of the MMAE payload drives induction of ICD. As an immune checkpoint ...

The new study, published April 21 in Nature Communications, bolsters evidence that lifesaving immune checkpoint inhibitors are effective across age groups despite age-related changes in the immune ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...